# OnCo record nct05009329 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05009329/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05009329", "NCT05009329" ;
  schema:name "A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China"@en ;
  schema:description "A phase 1/2 trial of Glecirasib in non-small-cell lung cancer, run by Allist Pharmaceuticals, Inc., active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05009329/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05009329> ;
  onco:status "active" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-07-26" ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/kras-g12c-nsclc/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/kras-inhibitors/> ;
  onco:drugs <https://onco.cc/drugs/glecirasib/> ;
  onco:companies <https://onco.cc/companies/allist/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-nct05009329-nat-med-2025/> .